Financial Data and Key Metrics Changes - For the full year 2025, sales increased by 8% on a reported basis and over 6% organically, while adjusted operating income grew by 13% [4][25] - Adjusted EPS increased by 21%, reflecting higher sales, improved profitability, and effective capital management [4][25] - In the fourth quarter, sales totaled $472 million, reflecting 5% growth on a reported basis and 2% growth on an organic basis [24] Business Line Data and Key Metrics Changes - Cardio and vascular sales increased by 11% to $284 million in Q4 2025, driven by acquisitions and strong demand in neurovascular [26] - Cardiac rhythm management and neuromodulation sales decreased by 2% to $167 million in Q4 2025, primarily due to lower demand from select emerging customers [27] Market Data and Key Metrics Changes - The medical device market remains attractive, with expected growth in mid-single digits for cardiovascular, neuromodulation, and cardiac rhythm management markets [10][11] - The company expects its underlying business to grow 4%-6% in line with the market, excluding the impact of three new products [6][35] Company Strategy and Development Direction - The company focuses on investing in differentiated capabilities and partnering with customers early in the design and development stage of new products [11][12] - A robust and diversified product development pipeline is oriented towards high-growth markets, with expectations of returning to above-market organic growth in 2027 [10][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to return to 200 basis points above-market organic growth in 2027, despite temporary headwinds in 2026 [7][39] - The company is maintaining a disciplined approach to capital management while investing in growth initiatives [21][39] Other Important Information - The company repurchased $50 million of common stock in Q4 2025 and announced an accelerated share repurchase program for an additional $50 million [4][5] - Adjusted effective tax rate for the full year was 17.2%, down from 18.3% in the prior year, reflecting tax benefits from R&D investment [30] Q&A Session Summary Question: Guidance on top line and the decision to lower the high end of the preliminary range - Management clarified that the adjustment was more about rounding than specific dynamics in January [42] Question: Return to operating income growth above sales growth in 2027 - Management expects margin expansion in the second half of 2026, with a return to above-market growth in 2027 [44] Question: Contribution from new products and their performance - Management indicated that the portfolio of products is expected to grow 15%-20% over the next 3-5 years, with good visibility on launch dates and expected revenues [47] Question: DSO increase and its implications - Management explained that the increase in DSO was due to limiting accounts receivable factoring to maintain financial flexibility [54] Question: Operating margin and its year-over-year decline - Management noted that fixed costs are more challenging to absorb with lower sales numbers, particularly in Q1 [60] Question: Visibility on customer forecasts and market dynamics - Management confirmed that discussions with customers align with their projections, indicating confidence in the guidance provided [66]

Integer (NYSE:ITGR) Q4 2025 Earnings call February 19, 2026 09:00 AM ET Speaker7Good morning, and thank you for standing by. Welcome to Energous, excuse me, Integer Holdings Corporation's fourth quarter 2025 earnings call. My name is Audra, and I will be your conference operator today. At this time, all participants are in a listen-only mode. After the prepared remarks, there will be a question-and-answer session. Please note this call is being recorded. I would now like to turn the conference over to Krist ...

Group 1 - Integer Holdings Corporation has appointed Michael Coyle to its Board of Directors, bringing over 40 years of leadership experience in the medical device industry [1][2] - Coyle's previous roles include president and CEO of iRhythm Technologies and executive vice president at Medtronic, along with leadership positions at St. Jude Medical and Eli Lilly [2] - He holds a master's degree from the Wharton School and a bachelor's degree from Case Western Reserve University, along with six U.S. patents related to cardiovascular medical devices [3] Group 2 - The Board of Integer regularly evaluates its composition to ensure it has the necessary skills and perspectives for growth [4] - Coyle's extensive experience is expected to significantly contribute to Integer's strategic initiatives and corporate culture [4] - The executive leadership team anticipates that Coyle's expertise will enhance Integer's contract development and manufacturing outsourcing strategy [4][5]